Clinical Trials - August 6, 2015
Biotie announces start of Phase 3 study
Finnish Biotie announces start of tozadenant Phase 3 Study of tozadenant, an investigational adenosine A2a receptor antagonist, in patients with Parkinson’s disease experiencing levodopa related end-of-dose “wearing-off”. The Phase 3 study (TOZ-PD) is a randomized, double-blind, placebo controlled trial that will evaluate efficacy and safety of tozadenant compared to placebo in 450 PD patients experiencing […]
Uncategorized - July 15, 2014
Biotie granted USD 2 million by Michael J. Fox foundation
Finnish biotech company Biotie has received two million dollars from a foundation set up by Hollywood star Michael J. Fox. The grant provides an opportunity to see if Biotie’s SYN120 treatment can slow the progress of dementia in patients with Parkinson’s Disease. The company is now planning a 16-week trial involving 80 patients at about 10 US sites. […]